ENTOD Pharmaceuticals has partnered with Infigo Eyecare Hospital, Mumbai, to introduce advanced treatments for under-eye dark circles and ocular aesthetics. This collaboration aims to integrate research-driven innovations into ophthalmic care, addressing periorbital health—a frequently overlooked aspect of dermatology and eye care.

The delicate skin around the eyes is prone to pigmentation, fine lines, and puffiness. Traditional treatments, primarily topical creams, offer limited absorption and only temporary relief. There is a growing demand for solutions that target the root causes of periorbital concerns rather than just surface-level improvements.

Nanotechnology has significantly advanced dermatological treatments by enhancing ingredient penetration, increasing bioavailability, and enabling sustained-release mechanisms. Periorbital hyperpigmentation (POH) affects nearly 30% of India’s population, particularly those with darker skin tones, influenced by genetics, lifestyle, and environmental factors.

According to Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, under-eye treatments have lagged behind skincare innovations. This partnership enables the development of targeted formulations with improved efficacy and long-lasting results. Dr. Shridhar R Thakur of Infigo Eyecare emphasized that combining medical expertise with advanced formulations ensures patients receive clinically validated therapies.

Beyond Mumbai, ENTOD and Infigo plan to expand these specialized treatment options to other cities, increasing awareness and advancing periorbital health research to improve aesthetic treatments for long-term patient benefits.